RB1 and prostate carcinoma: To confirm the activation of E2F signaling by the K450/451R mutant, we examined the expression of previously identified prostate cancer–specific E2F/Rb targets (37) and observed broad activation of those genes upon overexpression of the K450/451R mutant (Fig. 5F).